Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 39

Sort by

Sort Order Select

Journal Articles

Outcomes of hematopoietic stem cell transplantation in 813 pediatric patients with Fanconi anemia

Blood (2024) 144 (12): 1329–1342.

https://doi.org/10.1182/blood.2023022751

Published: 2024

Includes: Supplemental data

Journal Articles

A Single Centre Cohort Study of Monitoring B Cell Populations in the Bone Marrow and Peripheral Blood Post Tisagenlecleucel Therapy of Relapsed/Refractory Acute Lymphoblastic Leukaemia

Blood (2023) 142 (Supplement 1): 3508.

https://doi.org/10.1182/blood-2023-182730

Published: 2023

Journal Articles

Title: Risk Factors and Natural History of Vincristine Induced Neuropathy on UKALL 2011: A Randomised Controlled Trial of the Effect of Omitting Vincristine Pulses

Lucy Alderson, Lucy Waller, Mario Cortina Borja, Amy A Kirkwood, Vickaynne Carruthers, David Jamieson, Pam Kearns, Amrana Qureshi, Susan Baird, Jayashree Motwani, Rachael Hough, John Moppett, Ajay Vora, Gareth Veal, Sujith Samarasinghe

Blood (2023) 142 (Supplement 1): 2831.

https://doi.org/10.1182/blood-2023-181721

Published: 2023

Journal Articles

Routine Whole Genome Sequencing for All Children with Hematological Malignancies Defines a New Standard of Care - Data of the First 152 Cases from the NHS England Genomic Medicine Service

Blood (2023) 142 (Supplement 1): 3656.

https://doi.org/10.1182/blood-2023-186025

Published: 2023

Journal Articles

Blinatumomab As Toxicity Sparing First Line Treatment of Children and Young Persons with B-Precursor Acute Lymphoblastic Leukaemia (B-ALL)

Blood (2022) 140 (Supplement 1): 8987–8988.

https://doi.org/10.1182/blood-2022-162475

Published: 2022

Journal Articles

Eltrombopag in Pediatric Patients with Previously Untreated or Refractory/Relapsed Severe Aplastic Anemia: The Phase II Escalate Trial

Akiko Shimamura, Alexey Maschan, Carolyn Bennett, Jason E Farrar, Sujith Samarasinghe, Brigitte Strahm, Winfred C. Wang, Adrianna Vlachos, Charlotte M. Niemeyer, Timothy S. Olson, Denise D'Alessio, Elise Burmeister Getz, Tomasz Lawniczek, Yunnan Xu, David A. Williams

Blood (2022) 140 (Supplement 1): 705–707.

https://doi.org/10.1182/blood-2022-158214

Published: 2022

Journal Articles

Outcome of Haematopoietic Cell Transplantation in 813 Children with Fanconi Anaemia: A Study on Behalf of the EBMT Severe Aplastic Anaemia Working Party and Paediatric Disease Working Party

Blood (2022) 140 (Supplement 1): 657–659.

https://doi.org/10.1182/blood-2022-163140

Published: 2022

Journal Articles

High Dose Methotrexate Does Not Reduce the Risk of CNS Relapse in Children and Young Adults with Acute Lymphoblastic Leukaemia and Lymphoblastic Lymphoma. Results of the Randomised Phase III Study UKALL 2011

Amy A. Kirkwood, Nicholas Goulden, John Moppett, Sujith Samarasinghe, Jon Mee, Rachael Hough, Pamela R. Kearns, Sarah Lawson, Clare J. Rowntree, Ajay Vora

Blood (2022) 140 (Supplement 1): 516–518.

https://doi.org/10.1182/blood-2022-160129

Published: 2022

Journal Articles

Reduced Intensity Reinduction Followed By Blinatumomab Achieves Excellent MRD Clearance with Reduced Toxicity and Facilitates Timely Transplant in Children and Young People with Relapsed B-Precursor Acute Lymphoblastic Leukemia

Blood (2022) 140 (Supplement 1): 3268–3270.

https://doi.org/10.1182/blood-2022-162565

Published: 2022

Journal Articles

Predictors of Relapse Risk Do Not Influence Time to "Cure" in Children and Young Adults with Acute Lymphoblastic Leukaemia

Sujith Samarasinghe, Ajay Vora, Nicholas John Goulden, Grace Antony, Anthony V. Moorman

Blood (2021) 138 (Supplement 1): 2306.

https://doi.org/10.1182/blood-2021-145486

Published: 2021

Journal Articles

Outcomes of Children and Young Adults with Acute Lymphoblastic Leukaemia Administered Inotuzumab Pre CAR-T Therapy

Blood (2021) 138 (Supplement 1): 1743.

https://doi.org/10.1182/blood-2021-148820

Published: 2021

Journal Articles

ALL Maintenance Treatment for Early Loss of B-Cell Aplasia after Tisagenlecleucel Therapy

Blood (2021) 138 (Supplement 1): 3859.

https://doi.org/10.1182/blood-2021-152344

Published: 2021

Journal Articles

Ten Year Outcomes of UKALL 2003: A Randomised Clinical Trial of Adjusting Treatment Intensity Based on Minimal Residual Disease

Sujith Samarasinghe, Ajay Vora, Nicholas John Goulden, Grace Antony, Anthony V. Moorman

Blood (2021) 138 (Supplement 1): 364.

https://doi.org/10.1182/blood-2021-144806

Published: 2021

Journal Articles

Blinatumomab for infant acute lymphoblastic leukemia

Katherine Clesham, Vasudha Rao, Jack Bartram, Philip Ancliff, Sara Ghorashian, David O’Connor, Vesna Pavasovic, Anupama Rao, Sujith Samarasinghe, Michelle Cummins, Andrea Malone, Katharine Patrick, Denise Bonney, Beki James, Brenda Gibson, Ajay Vora

Blood (2020) 135 (17): 1501–1504.

https://doi.org/10.1182/blood.2019004008

Published: 2020

Journal Articles

A validated novel continuous prognostic index to deliver stratified medicine in pediatric acute lymphoblastic leukemia

Blood (2020) 135 (17): 1438–1446.

https://doi.org/10.1182/blood.2019003191

Published: 2020

Includes: Supplemental data

Journal Articles

Therapy of Paediatric B-ALL with a Fast Off Rate CD19 CAR Leads to Enhanced Expansion and Prolonged CAR T Cell Persistence in Patients with Low Bone Marrow Tumour Burden, and Is Associated with a Favourable Toxicity Profile

Blood (2019) 134 (Supplement_1): 225.

https://doi.org/10.1182/blood-2019-125009

Published: 2019

Journal Articles

Major Deviations in the Delivery of Induction Chemotherapy Are Associated with an Increased Risk of Relapse in Acute Lymphoblastic Leukaemia: Results from UKALL2003

Rachael E Hough, MD, Amy A Kirkwood, Sujith Samarasinghe, Clare J Rowntree, MBBS, PhD FRCP, FRCPath, Nicholas John Goulden, MD PhD MRCPath, Ajay Vora

Blood (2019) 134 (Supplement_1): 2579.

https://doi.org/10.1182/blood-2019-127223

Published: 2019

Journal Articles

Preliminary Outcomes of Children and Young Adults with Acute Lymphoblastic Leukaemia and Down Syndrome (DS-ALL) on UKALL 2011. Reduction in Treatment-Related Mortality with De-Escalated Therapy

Sara Ghorashian, FRCPath, PhD, Sujith Samarasinghe, Amy A Kirkwood, MSc, Rachael Hough, MD BMBS, FRCP, FRCPath, Clare Rowntree, MD, Sarah Lawson, MD, Nicholas John Goulden, MD PhD MRCPath, Emma Pond, PhD, Pamela R. Kearns, PhDFRCPC, Anthony V. Moorman, PhD, John Moppett, Ajay Vora, MD

Blood (2018) 132 (Supplement 1): 656.

https://doi.org/10.1182/blood-2018-99-118426

Published: 2018

Journal Articles

Excellent Response to Blinatumomab in Children and Young Adults with Refractory B Lineage Acute Lymphoblastic Leukaemia for Persistent MRD or after Debulking Chemotherapy for Higher Disease Burden

Vasudha Rao, MD, Katherine Clesham, Jack Luke Bartram, MD, Phil Ancliff, Sara Ghorashian, FRCPath, PhD, David O'Connor, Vesna Pavasovic, Anupama Rao, MD, Sujith Samarasinghe, Carole Cairns, David Marks, David Taussig, PhD MRCP, FRCPath, Ajay Vora, MD

Blood (2018) 132 (Supplement 1): 5201.

https://doi.org/10.1182/blood-2018-99-117051

Published: 2018

Journal Articles

Long-Term Follow-up of the Randomized Controlled Study in Patients with Newly Diagnosed Severe Aplastic Anemia Treated with ATG, Cyclosporine, with or without G-CSF: On Behalf of the SAA Working Party of the EBMT

André Tichelli, MD, Regis Peffault De Latour, Jakob R. Passweg, MD PhD, Cora Knol, Gérard Socié, MDPhD, Judith Marsh, Britta Hoechsmann, MD, Hubert Schrezenmeier, MD, Andrea Bacigalupo, MD, Sujith Samarasinghe, Alicia Rovo, MD, Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Dirk-Jan Eikema, Paul Bosman, Peter Bader, MD PhD, Antonio M. Risitano, MD PhD, Carlo Dufour, MD

Blood (2018) 132 (Supplement 1): 1307.

https://doi.org/10.1182/blood-2018-99-111811

Published: 2018

NARROW

Outcomes of hematopoietic stem cell transplantation in 813 pediatric patients with Fanconi anemia

A Single Centre Cohort Study of Monitoring B Cell Populations in the Bone Marrow and Peripheral Blood Post Tisagenlecleucel Therapy of Relapsed/Refractory Acute Lymphoblastic Leukaemia

Title: Risk Factors and Natural History of Vincristine Induced Neuropathy on UKALL 2011: A Randomised Controlled Trial of the Effect of Omitting Vincristine Pulses

Routine Whole Genome Sequencing for All Children with Hematological Malignancies Defines a New Standard of Care - Data of the First 152 Cases from the NHS England Genomic Medicine Service

Blinatumomab As Toxicity Sparing First Line Treatment of Children and Young Persons with B-Precursor Acute Lymphoblastic Leukaemia (B-ALL)

Eltrombopag in Pediatric Patients with Previously Untreated or Refractory/Relapsed Severe Aplastic Anemia: The Phase II Escalate Trial

Outcome of Haematopoietic Cell Transplantation in 813 Children with Fanconi Anaemia: A Study on Behalf of the EBMT Severe Aplastic Anaemia Working Party and Paediatric Disease Working Party

High Dose Methotrexate Does Not Reduce the Risk of CNS Relapse in Children and Young Adults with Acute Lymphoblastic Leukaemia and Lymphoblastic Lymphoma. Results of the Randomised Phase III Study UKALL 2011

Reduced Intensity Reinduction Followed By Blinatumomab Achieves Excellent MRD Clearance with Reduced Toxicity and Facilitates Timely Transplant in Children and Young People with Relapsed B-Precursor Acute Lymphoblastic Leukemia

Predictors of Relapse Risk Do Not Influence Time to "Cure" in Children and Young Adults with Acute Lymphoblastic Leukaemia

Outcomes of Children and Young Adults with Acute Lymphoblastic Leukaemia Administered Inotuzumab Pre CAR-T Therapy

ALL Maintenance Treatment for Early Loss of B-Cell Aplasia after Tisagenlecleucel Therapy

Ten Year Outcomes of UKALL 2003: A Randomised Clinical Trial of Adjusting Treatment Intensity Based on Minimal Residual Disease

Blinatumomab for infant acute lymphoblastic leukemia

A validated novel continuous prognostic index to deliver stratified medicine in pediatric acute lymphoblastic leukemia

Therapy of Paediatric B-ALL with a Fast Off Rate CD19 CAR Leads to Enhanced Expansion and Prolonged CAR T Cell Persistence in Patients with Low Bone Marrow Tumour Burden, and Is Associated with a Favourable Toxicity Profile

Major Deviations in the Delivery of Induction Chemotherapy Are Associated with an Increased Risk of Relapse in Acute Lymphoblastic Leukaemia: Results from UKALL2003

Preliminary Outcomes of Children and Young Adults with Acute Lymphoblastic Leukaemia and Down Syndrome (DS-ALL) on UKALL 2011. Reduction in Treatment-Related Mortality with De-Escalated Therapy

Excellent Response to Blinatumomab in Children and Young Adults with Refractory B Lineage Acute Lymphoblastic Leukaemia for Persistent MRD or after Debulking Chemotherapy for Higher Disease Burden

Long-Term Follow-up of the Randomized Controlled Study in Patients with Newly Diagnosed Severe Aplastic Anemia Treated with ATG, Cyclosporine, with or without G-CSF: On Behalf of the SAA Working Party of the EBMT

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only